Stockreport

The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF 59% Complete Response in patients with low-grade upper tract urothelial cancerKaplan-Meier analysis, based on interim data, estimated 12-month durability at 84% Results [Read more]